The Impact of Cetuximab Plus AKT- Or mTOR- Inhibitor in a Patient-Derived Colon Cancer Cell Model With Wild-Type RAS and PIK3CA Mutation

Journal of Cancer - Australia
doi 10.7150/jca.19458
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Ivyspring International Publisher

Related search

Antitumor Activity of Sorafenib Plus CDK4/6 Inhibitor in Pancreatic Patient Derived Cell With KRAS Mutation

Journal of Cancer
Oncology
2018English

Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- And PIK3CA- Wild-Type Metastatic Colorectal Cancer: The AGITG Randomised Phase II ICECREAM Study

Clinical Colorectal Cancer
OncologyGastroenterology
2018English

Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study

Clinical Colorectal Cancer
OncologyGastroenterology
2017English

Control of the MYC-eIF4E Axis Plus mTOR Inhibitor Treatment in Small Cell Lung Cancer

BMC Cancer
Cancer ResearchOncologyGenetics
2015English

Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer

JAMA Oncology
Cancer ResearchOncology
2019English

Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-Line Cetuximab and Irinotecan

JAMA Oncology
Cancer ResearchOncology
2019English

Mutant and Wild-Type Ras: Co-Conspirators in Cancer

Cancer Discovery
Oncology
2013English

FOLFIRI Plus Panitumumab in the Treatment of Wild-Type KRAS and Wild-Type NRAS Metastatic Colorectal Cancer

World Journal of Surgical Oncology
SurgeryOncology
2018English

P16 Hypermethylation and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients With Metastatic Colorectal Cancer

Cancer Research and Treatment
Cancer ResearchOncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy